Key result
Non-inhibiting antidepressants like escitalopram are safer than CYP3A4 inhibitors with rivaroxaban by avoiding drug interactions.
Why the study?
Pharmacokinetic knowledge of drug interactions between rivaroxaban and antidepressants is needed due to frequent coexistence of depression and cardiovascular diseases treated with oral anticoagulants.
Which antidepressants are safe to use in patients taking rivaroxaban to avoid pharmacokinetic interactions?
Which antidepressants are safe to use in patients taking rivaroxaban to avoid pharmacokinetic interactions?
When treating depression in patients on rivaroxaban, antidepressants with minimal CYP450 inhibition (e.g., escitalopram, citalopram) should be preferred over CYP3A4 inhibitors (e.g., fluoxetine, sertraline) to avoid pharmacokinetic interactions.
Answers are grounded in this paper and cite their sources.
May guide antidepressant selection with rivaroxaban; leaves open prospective trials to confirm interaction risks.
The use of Oral Anticoagulants (OAC) is recommended for stroke prevention. Rivaroxaban is a new generation oral anticoagulant. Depression and anxiety are psychiatric disorders which frequently coexist with the Coronary Artery Disease (CAD) and other cardiovascular diseases. In the last decades, there has been an increase in the use of antidepressants. This literature review aims to provide a general view of pharmacokinetic knowledge of drug interactions between rivaroxaban and antidepressants. Since rivaroxaban is metabolized by CYP3A4, the use of antidepressants that are inhibitors of this isoenzyme, such as fluoxetine, sertraline, paroxetine and fluvoxamine must be avoided. Based on drug interactions in cytochrome p450, it has been concluded that the use of escitalopram, citalopram, venlafaxine, mirtazapine or milnacipran would be safer in these patients since these drugs have a minimum CYP 450 inhibition potential.
No takes yet. Share an insight, caveat, or question.
Carlos Clayton TAA rres Aguiar (2016) conducted a review in Depression in patients on anticoagulation therapy (rivaroxaban). Antidepressants was evaluated on Pharmacokinetic drug interactions. CYP3A4-inhibiting antidepressants like fluoxetine and sertraline should be avoided with rivaroxaban, whereas escitalopram, citalopram, venlafaxine, mirtazapine, or milnacipran are safer alternatives.
Synapse has enriched 10 related papers. Consider them for comparative context: